Amanote Research
Register
Sign In
JCSE01.09 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.217
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
Y. Wu
Q. Zhou
X. Zhang
H. Tu
B. Gan
B. Wang
C. Xu
H. Chen
M. Zheng
Z. Wang
X. Bai
Y. Sun
A. Myers
X. Lv
Y. Chakraborti
S. Zhao
J.-. Yang
J. Callister
Publisher
Elsevier BV
Related search
P1.01-97 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Binimetinib Plus Gemcitabine and Cisplatin Phase I/Ii Trial in Patients With Advanced Biliary Cancers
Clinical Cancer Research
Cancer Research
Oncology
Designing a Preliminary Adaptive Study to Inform a Biomarker Trial in Psoriasis
Trials
Medicine
Pharmacology
Behavioral Duality in an Integrated Agent
Frontiers in Human Neuroscience
Mental Health
Neuropsychology
Physiological Psychology
Neurology
Behavioral Neuroscience
Psychiatry
Biological Psychiatry
Selection Bias in Cluster Trial
British Medical Journal
Medicine
Clinical and Biomarker Outcomes of the Phase II Vandetanib Study From the BATTLE Trial
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Integrated Cervical Cancer Screening in Mayuge District Uganda (ASPIRE Mayuge): A Pragmatic Sequential Cluster Randomized Trial Protocol
BMC Public Health
Environmental
Public Health
Occupational Health
Brain Natriuretic Peptide in Pulmonary Arterial Hypertension: Biomarker and Potential Therapeutic Agent
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Hybrid Control of a Three-Agent Network Cluster
